Filing Overview
Replimune Group, Inc. filed a Form 8-K under Item 5.02 regarding the appointment of Jean Franchi as Chief Financial Officer. The employment agreement was dated November 27, 2019, became effective December 9, 2019, and the appointment was announced on December 9, 2019. Replimune is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol REPL.
Key Compensation and Employment Terms
- Annual base salary of $425,000.
- Eligibility for an annual discretionary bonus tied to individual and corporate performance goals, with a target of 40% of annualized base salary.
- $50,000 sign-on bonus payable within 30 days after the effective date, subject to prorated repayment if Ms. Franchi leaves under specified circumstances before the first anniversary.
- Nonqualified stock option to purchase 180,000 shares of common stock at the closing market price on the grant date. The option vests over four years: 25% after one year and the remainder monthly over the following three years.
- Standard benefits, expense reimbursement, paid time off, confidentiality obligations, and one-year post-employment non-competition and non-solicitation covenants.
Severance and Change-of-Control Provisions
- If terminated without Cause or if Ms. Franchi resigns for Good Reason, subject to a release of claims, she is generally entitled to 12 months of base salary continuation and a lump-sum payment covering specified 12-month healthcare premiums.
- If such termination occurs on or within one year following a Change of Control, she is generally entitled to 12 months of base salary plus the target annual bonus for the termination year, together with the healthcare payment.
- The agreement includes a tax-protection provision for potential Section 280G excess parachute payments, reducing payments only when doing so provides a greater after-tax benefit.
Management Changes and Financial Information
- Ms. Franchi replaces Stephen Gorgol as Principal Financial Officer and Philip Astley-Sparke as Secretary and Treasurer.
- Ms. Franchi will also serve as Replimune’s Compliance Officer.
- The filing reports no qualifying family relationships or related-party transactions involving Ms. Franchi.
- This 8-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It also does not provide financial guidance or an updated business outlook.
Material Changes and Unusual Items
The material event is the appointment of a new CFO and the associated compensation, equity award, severance, and change-of-control arrangements. The filing includes no reported change to business performance, capital resources, or financial results.
Investor Verification Items
- Review Exhibit 10.1 for the complete definitions of Cause, Good Reason, Change of Control, release requirements, and other employment terms.
- Verify the stock-option grant-date share price and subsequent equity-compensation disclosures.
- Assess the potential cash and equity dilution associated with the salary, bonus, sign-on payment, option award, and severance provisions.
- Reconcile the November 27 report date with the December 9 appointment announcement and effective date.